Latest On Lipocine Inc (LPCN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-16 16:00 EST | News | Lipocine stock dips after bridging study data of LPCN 1154 for postpartum depression | N/A |  |
| 2023-05-11 07:42 EST | News | Lipocine GAAP EPS of -$0.04 misses by $0.01 | N/A | |
| 2023-03-10 10:25 EST | News | Lipocine GAAP EPS of -$0.13 in-line, revenue of $0.5M misses by $0.91M | N/A | |
| 2022-11-10 02:31 EST | News | Lipocine GAAP EPS of -$0.03 in-line | N/A | |
| 2022-09-26 22:11 EST | News | Lipocine announces plans to focus on treating CNS disorders, shares rise ~5% | N/A | |
| 2022-08-09 04:47 EST | News | Lipocine GAAP EPS of -$0.04 in-line, revenue of $0.5M beats by $0.24M | N/A | |
| 2022-06-14 18:59 EST | News | Lipocine stock rises premarket after being granted two U.S. patents | N/A | |
| 2022-05-09 12:48 EST | News | Lipocine GAAP EPS of -$0.04 misses by $0.02 | N/A | |
| 2022-03-30 03:57 EST | News | Antares wins full FDA approval for testosterone replacement therapy | N/A | |
| 2022-03-10 02:03 EST | News | Lipocine GAAP EPS of -$0.01, revenue of $16.1M | N/A | |
| 2022-02-03 13:55 EST | News | Lipocine announces FDA accepted the marketing application for Tlando | N/A | |
| 2021-12-22 19:56 EST | News | Dosing underway in Lipocine's mid-stage LPCN 1148 study for liver cirrhosis | N/A | |
| 2021-11-11 08:53 EST | News | Lipocine Is One To Watch Based On Possible FDA Approval Of TLANDO And NASH Data | N/A | |
| 2021-11-04 12:10 EST | News | Lipocine shares jump 9% after FDA Fast Track status for LPCN 1144 NASH treatment | N/A | |
| 2021-10-27 21:32 EST | News | Warning: LPCN is at high risk of performing badly | N/A | |
| 2021-10-18 17:20 EST | News | Lipocine shares rise after TLANDO licensing agreement with Antares Pharma | N/A | |
| 2021-09-28 19:43 EST | News | FDA affirms class 1 NDA resubmission for Lipocine's Tlando | N/A | |
| 2021-08-25 20:22 EST | News | Lipocine discloses mid-stage data for NASH candidate | N/A | |
| 2021-08-06 06:20 EST | News | Lipocine EPS misses by $0.03 | N/A | |
| 2021-07-21 15:06 EST | News | Lipocine competitor prevails in patent infringement lawsuit for Jatenzo | N/A | |
| 2021-07-21 14:54 EST | News | Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression | N/A | |
| 2021-07-21 14:48 EST | News | Cantor initiates Lipocine with an overweight rating, sees 121% upside | N/A | |
| 2021-07-21 14:30 EST | News | Lipocine enters settlement and license agreement with Clarus Therapeutics | N/A | |
| 2021-05-06 15:07 EST | News | Lipocine EPS beats by $0.01 | N/A | |
| 2021-03-12 08:03 EST | Earnings Estimate | An EPS average of $0.24 is estimated for the 2022 year. | Buy | |
| 2021-03-12 08:03 EST | Earnings Estimate | An EPS average of -$0.06 is estimated for the quarter ending on June 30, 2021. | N/A | |
| 2021-03-12 08:03 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-05 01:04 EST | News | Lipocine shares up after LPCN 1144 preclinical study results | N/A | |
| 2021-01-25 19:13 EST | News | Lipocine under pressure on launching underwritten public offering | N/A | |
| 2021-01-13 01:15 EST | News | Lipocine announces positive results from phase 2biopsy-confirmed NASH study | N/A | |
| 2021-01-06 16:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-14 21:25 EST | News | Lipocine: Imminent Catalysts In NASH And Oral Testosterone Replacement Therapy Make For A Strong Buy | N/A | |
| 2020-12-11 12:04 EST | Analyst Rating | The Analyst Target Price has increased from $3 to $5.33. | Buy | |
| 2020-12-09 20:58 EST | News | FDA Ok's Lipocine's testosterone replacement therapy, tentatively | N/A | |
| 2020-11-26 20:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-14 04:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-12 04:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-11 12:22 EST | Earnings Estimate | An EPS average of -$0.04 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-11-10 18:47 EST | News | Lipocine EPS misses by $0.01 | N/A | |
| 2020-11-07 16:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 12:53 EST | News | Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection | N/A | |
| 2020-09-26 13:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 05:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-29 05:11 EST | News | Lipocine under pressure on extended timeline for FDA review of Tlando application | N/A | |
| 2020-08-22 03:47 EST | News | Seeking Alpha Catalyst Watch | N/A | |
| 2020-08-14 09:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-08 01:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-07 05:06 EST | Analyst Rating | The Analyst Target Price has decreased from $3.67 to $3. | Neutral | |
| 2020-07-31 01:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 17:37 EST | Financials | Company financials have been released. | Neutral | |
About Lipocine Inc (LPCN):
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
General
- Name Lipocine Inc
- Symbol LPCN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 11
- Last Split Factor1:100
- Last Split Date2013-07-25
- Fiscal Year EndDecember
- IPO Date2013-10-22
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.lipocine.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 286.68
- Price/Book (Most Recent Quarter) 10.99
- Enterprise Value Revenue 441.02
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.24
- Next Year EPS Estimate $0.23
- Next Quarter EPS Estimate -$0.07
- Return on Assets -50%
- Return on Equity -194%
- Earnings Per Share -$0.55
- Revenue Per Share $0
- Gross Profit -5053695
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 150.09 million
- EBITDA -11983663
- Analyst Target Price $5.33
- Book Value Per Share $0.22
View More
Share Statistics
- Shares Outstanding 88.29 million
- Shares Float 86.12 million
- % Held by Insiders 331%
- % Held by Institutions 10.99%
- Shares Short 3.96 million
- Shares Short Prior Month 4.74 million
- Short Ratio 0.68
- Short % of Float 5%
- Short % of Shares Outstanding 5%
View More
Technicals
- Beta 0.53
- 52 Week High $2.42
- 52 Week Low $0.36
- 50 Day Moving Average 1.72
- 200 Day Moving Average 1.53
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Lipocine Inc (LPCN) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Lipocine Inc (LPCN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-11 | $N/A | -$0.06 | -$0.06 | 5.21% |
| 2020-09-30 | 2020-11-10 | $N/A | -$0.07 | -$0.06 | -16.67% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.13 | -$0.07 | -85.71% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.14 | -$0.08 | -75% |
| 2019-12-31 | 2020-03-13 | $N/A | -$0.10 | -$0.10 | 0% |
| 2019-09-30 | 2019-11-12 | $164990 | -$0.12 | -$0.21 | 42.86% |
| 2019-06-30 | 2019-08-07 | $N/A | -$0.14 | -$0.21 | 33.33% |
| 2019-03-31 | 2019-05-08 | $N/A | -$0.14 | -$0.15 | 3.45% |
| 2018-12-31 | 2019-03-06 | $428031 | -$0.15 | -$0.13 | -12.53% |
| 2018-09-30 | 2018-11-07 | $N/A | -$0.12 | -$0.19 | 36.84% |
| 2018-06-30 | 2018-08-07 | $-428031 | -$0.15 | -$0.25 | 39.02% |
| 2018-03-31 | 2018-05-07 | $428031 | -$0.13 | -$0.21 | 38.82% |
| 2017-12-31 | 2018-03-12 | $N/A | -$0.25 | -$0.23 | -8.7% |
| 2017-09-30 | 2017-11-08 | $N/A | -$0.22 | -$0.23 | 3.3% |
| 2017-06-30 | 2017-08-07 | $N/A | -$0.31 | -$0.31 | 0% |
| 2017-03-31 | 2017-05-08 | $N/A | -$0.26 | -$0.30 | 13.33% |
| 2016-12-31 | 2017-03-06 | $N/A | -$0.16 | -$0.24 | 34.43% |
| 2016-09-30 | 2016-11-08 | $N/A | -$0.18 | -$0.29 | 38.78% |
| 2016-06-30 | 2016-08-09 | $N/A | -$0.32 | -$0.36 | 11.72% |
| 2016-03-31 | 2016-05-09 | $N/A | -$0.38 | -$0.33 | -15.15% |
| 2015-12-31 | 2016-03-10 | $N/A | -$0.27 | -$0.33 | 18.18% |
| 2015-09-30 | 2015-11-12 | $N/A | -$0.35 | -$0.25 | -40% |
| 2015-06-30 | 2015-08-11 | $N/A | -$0.26 | -$0.20 | -30% |
| 2015-03-31 | 2015-05-07 | $N/A | -$0.23 | -$0.25 | 8% |
| 2014-12-31 | 2015-03-11 | $N/A | -$0.32 | -$0.27 | -18.52% |
| 2014-09-30 | 2014-11-10 | $N/A | -$0.32 | -$0.55 | 41.82% |
| 2014-06-30 | 2014-08-13 | $N/A | -$0.55 | -$0.42 | -30.95% |
| 2014-03-31 | 2014-05-14 | $N/A | -$0.41 | -$0.41 | 0% |
| 2013-12-31 | 2014-03-31 | $N/A | -$0.30 | -$0.27 | -11.11% |
| 2013-09-30 | 2013-11-27 | $N/A | -$0.39 | ||
| 2013-06-30 | 2013-08-28 | $N/A | -$0.09 | ||
| 2013-03-31 | 2013-03-31 | $N/A | -$0.09 | ||
| 2012-12-31 | 2012-12-31 | $7.71 million | -$0.14 | ||
| 2012-09-30 | 2012-09-30 | $N/A | -$0.16 | ||
| 2012-06-30 | 2012-06-30 | $-7710000 | -$1.75 |
Lipocine Inc (LPCN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 2.48 million | N/A | N/A | N/A | 5.72 million |
| Income Before Tax | -4.51 million | N/A | N/A | N/A | -3.29 million |
| Selling General Administrative | 2.32 million | N/A | N/A | N/A | 1.61 million |
| Gross Profit | N/A | N/A | N/A | N/A | 3.88 million |
| Ebit | -4.51 million | N/A | N/A | N/A | -3.45 million |
| Operating Income | -4.8 million | N/A | N/A | N/A | -3.45 million |
| Income Tax Expense | N/A | N/A | N/A | 200 | -500 |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | -3.88 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 156177 |
| Net Income From Continuing Operations | -4.51 million | N/A | N/A | N/A | -3.29 million |
| Net Income Applicable to Common Shares | -4.51 million | -4.31 million | -6.37 million | -5.77 million | -3.29 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -1.4 million | N/A | N/A | 557405 | 5.97 million |
| Change to Liabilities | N/A | -748083 | N/A | -178205 | 1.24 million |
| Total Cash Flow from Investing Activities | N/A | -4.02 million | N/A | 557405 | 5.97 million |
| Net Borrowings | N/A | -44241 | N/A | -833334 | -833332 |
| Total Cash Flow from Financial Activities | 4.66 million | N/A | N/A | 5.81 million | -173455 |
| Change to Operating Activities | N/A | 482333 | N/A | 111298 | -1.05 million |
| Change in Cash | -899632 | N/A | N/A | 3.06 million | 3 million |
| Total Cash from Operating Activities | -4.16 million | -4.08 million | N/A | -3.31 million | -2.8 million |
| Depreciation | 799 | N/A | N/A | 3861 | 3860 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | 2.56 million | N/A | 47079 | 67876 |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 10.01 million | N/A | N/A | N/A | 13.37 million |
| Total Stockholder Equity | 15.34 million | N/A | N/A | N/A | 6.29 million |
| Other Current Liabilities | 3.43 million | N/A | N/A | N/A | N/A |
| Total Assets | 25.35 million | N/A | N/A | N/A | 19.66 million |
| Common Stock | 7005 | 6569 | 6138 | 4786 | 3766 |
| Other Current Assets | 661258 | 5 million | N/A | N/A | 5 million |
| Retained Earnings | -172.03 million | -167.52 million | -163.21 million | -156.84 million | -151.07 million |
| Other Liabilities | N/A | 1.3 million | 2.17 million | 5.69 million | 4.59 million |
| Other Assets | N/A | 23753 | 23753 | 23753 | 23753 |
| Cash | 24.22 million | N/A | N/A | N/A | 9.73 million |
| Total Current Liabilities | 6.58 million | 5.79 million | N/A | N/A | 4.96 million |
| Other Stockholder Equity | N/A | 475 | -104 | N/A | -38 |
| Property, Plant & Equipment | N/A | 1157 | 1956 | 2755 | 3554 |
| Total Current Assets | 25.33 million | 24.73 million | N/A | N/A | 19.63 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 15.34 million | 14.51 million | 13.08 million | 6.55 million | 6.29 million |
| Short Term Investments | 449992 | N/A | N/A | N/A | 4.34 million |
| Long Term Debt | N/A | N/A | N/A | N/A | 3.81 million |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 3.25 million | 1.05 million | N/A | N/A | 1.18 million |
Lipocine Inc (LPCN) Chart:
Lipocine Inc (LPCN) News:
Below you will find a list of latest news for Lipocine Inc (LPCN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Lipocine Inc (LPCN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest LPCN Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:31 PM EST | 3 | $0.8492 |
| Jun 13, 2022 7:39 PM EST | 100 | $0.85 |
| Jun 13, 2022 7:46 PM EST | 100 | $0.84 |
| Jun 13, 2022 7:49 PM EST | 100 | $0.835 |
| Jun 13, 2022 7:57 PM EST | 1 | $0.85 |
Lipocine Inc (LPCN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859920000594/0001638599-20-000594-index.htm |
| 2020-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1535955/000103738920000059/0001037389-20-000059-index.htm |
| 2019-10-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465919055092/0001104659-19-055092-index.htm |
| 2019-10-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465919055094/0001104659-19-055094-index.htm |
| 2019-10-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465919056511/0001104659-19-056511-index.htm |
| 2019-11-07 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1535955/000110465919060839/0001104659-19-060839-index.htm |
| 2019-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465919061367/0001104659-19-061367-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465919061976/0001104659-19-061976-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1535955/000110465919062585/0001104659-19-062585-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465919062605/0001104659-19-062605-index.htm |
| 2019-11-13 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1535955/000110465919063286/0001104659-19-063286-index.htm |
| 2019-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465919063293/0001104659-19-063293-index.htm |
| 2019-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465919063788/0001104659-19-063788-index.htm |
| 2019-11-14 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1535955/000110465919064164/0001104659-19-064164-index.htm |
| 2019-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465919064172/0001104659-19-064172-index.htm |
| 2019-11-15 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1535955/000110465919064670/0001104659-19-064670-index.htm |
| 2019-11-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465919065076/0001104659-19-065076-index.htm |
| 2019-12-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465919076463/0001104659-19-076463-index.htm |
| 2020-01-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920002836/0001104659-20-002836-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920003237/0001104659-20-003237-index.htm |
| 2020-02-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920011006/0001104659-20-011006-index.htm |
| 2020-02-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920016289/0001104659-20-016289-index.htm |
| 2020-02-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920024088/0001104659-20-024088-index.htm |
| 2020-02-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920024503/0001104659-20-024503-index.htm |
| 2020-02-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1535955/000110465920025053/0001104659-20-025053-index.htm |
| 2020-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920025054/0001104659-20-025054-index.htm |
| 2020-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920026183/0001104659-20-026183-index.htm |
| 2020-03-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920028911/0001104659-20-028911-index.htm |
| 2020-03-13 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1535955/000110465920032764/0001104659-20-032764-index.htm |
| 2020-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920032766/0001104659-20-032766-index.htm |
| 2020-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920038554/0001104659-20-038554-index.htm |
| 2020-04-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920041546/0001104659-20-041546-index.htm |
| 2020-04-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920044865/0001104659-20-044865-index.htm |
| 2020-04-10 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1535955/000110465920045542/0001104659-20-045542-index.htm |
| 2020-04-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920047925/0001104659-20-047925-index.htm |
| 2020-04-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920049014/0001104659-20-049014-index.htm |
| 2020-04-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1535955/000110465920051968/0001104659-20-051968-index.htm |
| 2020-05-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920056552/0001104659-20-056552-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1535955/000110465920057762/0001104659-20-057762-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920057765/0001104659-20-057765-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920059149/0001104659-20-059149-index.htm |
| 2020-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920060470/0001104659-20-060470-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920062094/0001104659-20-062094-index.htm |
| 2020-06-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920071991/0001104659-20-071991-index.htm |
| 2020-07-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920082920/0001104659-20-082920-index.htm |
| 2020-07-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920084655/0001104659-20-084655-index.htm |
| 2020-07-30 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1535955/000110465920088369/0001104659-20-088369-index.htm |
| 2020-07-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920088699/0001104659-20-088699-index.htm |
| 2020-08-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920089327/0001104659-20-089327-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1535955/000110465920091145/0001104659-20-091145-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920091147/0001104659-20-091147-index.htm |
| 2020-08-06 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1535955/000110465920091148/0001104659-20-091148-index.htm |
| 2020-08-21 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1535955/000110465920097634/0001104659-20-097634-index.htm |
| 2020-08-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920097968/0001104659-20-097968-index.htm |
| 2020-08-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920100155/0001104659-20-100155-index.htm |
| 2020-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920104609/0001104659-20-104609-index.htm |
| 2020-09-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920106757/0001104659-20-106757-index.htm |
| 2020-09-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920106761/0001104659-20-106761-index.htm |
| 2020-10-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920111983/0001104659-20-111983-index.htm |
| 2020-10-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920114131/0001104659-20-114131-index.htm |
| 2020-10-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920114712/0001104659-20-114712-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920121590/0001104659-20-121590-index.htm |
| 2020-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000110465920122166/0001104659-20-122166-index.htm |
| 2019-05-22 | PX14A6G | Notice of exempt solicitation submitted by non-management | https://www.sec.gov/Archives/edgar/data/1535955/000114036119009636/0001140361-19-009636-index.htm |
| 2020-05-20 | PX14A6G | Notice of exempt solicitation submitted by non-management | https://www.sec.gov/Archives/edgar/data/1535955/000114036120012025/0001140361-20-012025-index.htm |
| 2018-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418013983/0001144204-18-013983-index.htm |
| 2018-03-12 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1535955/000114420418014093/0001144204-18-014093-index.htm |
| 2018-04-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1535955/000114420418022850/0001144204-18-022850-index.htm |
| 2018-05-04 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1535955/000114420418025219/0001144204-18-025219-index.htm |
| 2018-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1535955/000114420418025522/0001144204-18-025522-index.htm |
| 2018-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418025524/0001144204-18-025524-index.htm |
| 2018-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418026332/0001144204-18-026332-index.htm |
| 2018-06-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418033157/0001144204-18-033157-index.htm |
| 2018-06-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418034049/0001144204-18-034049-index.htm |
| 2018-06-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418036342/0001144204-18-036342-index.htm |
| 2018-06-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418036675/0001144204-18-036675-index.htm |
| 2018-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1535955/000114420418042231/0001144204-18-042231-index.htm |
| 2018-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418042232/0001144204-18-042232-index.htm |
| 2018-08-08 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1535955/000114420418042552/0001144204-18-042552-index.htm |
| 2018-08-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418045349/0001144204-18-045349-index.htm |
| 2018-08-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418046847/0001144204-18-046847-index.htm |
| 2018-09-20 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1535955/000114420418050132/0001144204-18-050132-index.htm |
| 2018-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418051675/0001144204-18-051675-index.htm |
| 2018-10-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418053318/0001144204-18-053318-index.htm |
| 2018-11-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418056795/0001144204-18-056795-index.htm |
| 2018-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418057174/0001144204-18-057174-index.htm |
| 2018-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1535955/000114420418057761/0001144204-18-057761-index.htm |
| 2018-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418057762/0001144204-18-057762-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418058127/0001144204-18-058127-index.htm |
| 2018-11-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418058725/0001144204-18-058725-index.htm |
| 2018-12-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418065510/0001144204-18-065510-index.htm |
| 2018-12-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418065819/0001144204-18-065819-index.htm |
| 2018-12-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420418066651/0001144204-18-066651-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419000774/0001144204-19-000774-index.htm |
| 2019-01-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419001492/0001144204-19-001492-index.htm |
| 2019-01-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419001913/0001144204-19-001913-index.htm |
| 2019-01-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419002177/0001144204-19-002177-index.htm |
| 2019-01-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419002508/0001144204-19-002508-index.htm |
| 2019-01-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419002959/0001144204-19-002959-index.htm |
| 2019-02-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419007530/0001144204-19-007530-index.htm |
| 2019-03-06 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1535955/000114420419012434/0001144204-19-012434-index.htm |
| 2019-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419012435/0001144204-19-012435-index.htm |
| 2019-03-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419012674/0001144204-19-012674-index.htm |
| 2019-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419013395/0001144204-19-013395-index.htm |
| 2019-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419014460/0001144204-19-014460-index.htm |
| 2019-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419015861/0001144204-19-015861-index.htm |
| 2019-03-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419016088/0001144204-19-016088-index.htm |
| 2019-03-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419016413/0001144204-19-016413-index.htm |
| 2019-04-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419017898/0001144204-19-017898-index.htm |
| 2019-04-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419019156/0001144204-19-019156-index.htm |
| 2019-04-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1535955/000114420419022112/0001144204-19-022112-index.htm |
| 2019-05-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419022665/0001144204-19-022665-index.htm |
| 2019-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1535955/000114420419024378/0001144204-19-024378-index.htm |
| 2019-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419024380/0001144204-19-024380-index.htm |
| 2019-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419025779/0001144204-19-025779-index.htm |
| 2019-05-15 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1535955/000114420419026336/0001144204-19-026336-index.htm |
| 2019-05-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419028428/0001144204-19-028428-index.htm |
| 2019-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419030684/0001144204-19-030684-index.htm |
| 2019-06-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419032049/0001144204-19-032049-index.htm |
| 2019-06-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419032136/0001144204-19-032136-index.htm |
| 2019-07-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419035466/0001144204-19-035466-index.htm |
| 2019-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1535955/000114420419038038/0001144204-19-038038-index.htm |
| 2019-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419038040/0001144204-19-038040-index.htm |
| 2019-08-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419041715/0001144204-19-041715-index.htm |
| 2019-09-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419045547/0001144204-19-045547-index.htm |
| 2019-09-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419045549/0001144204-19-045549-index.htm |
| 2019-09-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419046380/0001144204-19-046380-index.htm |
| 2019-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1535955/000114420419046623/0001144204-19-046623-index.htm |
| 2020-02-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1535955/000139382520000065/0001393825-20-000065-index.htm |
| 2019-11-22 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1535955/000153561019000102/0001535610-19-000102-index.htm |
| 2020-01-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1535955/000153561020000037/0001535610-20-000037-index.htm |
| 2020-02-25 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1535955/000153561020000075/0001535610-20-000075-index.htm |
| 2018-06-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859918000697/0001638599-18-000697-index.htm |
| 2018-06-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859918000698/0001638599-18-000698-index.htm |
| 2018-06-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859918000699/0001638599-18-000699-index.htm |
| 2018-06-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859918000700/0001638599-18-000700-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859918001326/0001638599-18-001326-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859918001327/0001638599-18-001327-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000557/0001638599-19-000557-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000608/0001638599-19-000608-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000609/0001638599-19-000609-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000610/0001638599-19-000610-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000611/0001638599-19-000611-index.htm |
| 2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000966/0001638599-19-000966-index.htm |
| 2019-11-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000975/0001638599-19-000975-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859919001010/0001638599-19-001010-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859919001011/0001638599-19-001011-index.htm |
| 2019-12-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859919001020/0001638599-19-001020-index.htm |
| 2020-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859920000002/0001638599-20-000002-index.htm |
| 2020-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859920000105/0001638599-20-000105-index.htm |
| 2020-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859920000106/0001638599-20-000106-index.htm |
| 2020-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859920000313/0001638599-20-000313-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859920000591/0001638599-20-000591-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859920000592/0001638599-20-000592-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859920000593/0001638599-20-000593-index.htm |
| 2020-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1535955/000163859920000594/0001638599-20-000594-index.htm |
Lipocine Inc (LPCN) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Lipocine Inc (LPCN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 331%Institutional Ownership: 1099%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-12-04 | MORGAN R BROWN | EVP and Chief Financial Office | Sell | 17,250.00 | 0.41 | 7,075.95 | 63,812.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919001011/0001638599-19-001011-index.htm |
| 2020-03-17 | John W. Higuchi | Director | Buy | 220,000.00 | 0.32 | 69,542.00 | 696,498.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859920000313/0001638599-20-000313-index.htm |
| 2019-05-24 | Mahesh V. Patel | President and CEO | Buy | 4,527.00 | 1.58 | 7,152.66 | 726,639.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000557/0001638599-19-000557-index.htm |
| 2019-05-24 | Mahesh V. Patel | President and CEO | Buy | 2,500.00 | 1.59 | 3,975.00 | 729,139.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000557/0001638599-19-000557-index.htm |
| 2019-05-24 | Mahesh V. Patel | President and CEO | Buy | 473.00 | 1.60 | 756.80 | 729,612.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000557/0001638599-19-000557-index.htm |
| 2019-05-24 | Mahesh V. Patel | President and CEO | Buy | 2,500.00 | 1.64 | 4,100.00 | 732,112.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000557/0001638599-19-000557-index.htm |
| 2019-11-18 | Mahesh V. Patel | CEO and President | Buy | 4,931.00 | 0.40 | 1,971.91 | 737,043.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000966/0001638599-19-000966-index.htm |
| 2019-11-18 | Mahesh V. Patel | CEO and President | Buy | 40,259.00 | 0.40 | 16,103.60 | 777,302.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000966/0001638599-19-000966-index.htm |
| 2019-11-18 | Mahesh V. Patel | CEO and President | Buy | 4,810.00 | 0.42 | 2,019.24 | 782,112.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000966/0001638599-19-000966-index.htm |
| 2019-11-26 | Mahesh V. Patel | President and CEO | Buy | 1,272.00 | 0.43 | 542.51 | 783,384.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000975/0001638599-19-000975-index.htm |
| 2019-11-26 | Mahesh V. Patel | President and CEO | Buy | 700.00 | 0.43 | 298.62 | 784,084.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000975/0001638599-19-000975-index.htm |
| 2019-11-26 | Mahesh V. Patel | President and CEO | Buy | 1,100.00 | 0.43 | 469.70 | 785,184.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000975/0001638599-19-000975-index.htm |
| 2019-11-26 | Mahesh V. Patel | President and CEO | Buy | 21,928.00 | 0.43 | 9,385.18 | 807,112.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919000975/0001638599-19-000975-index.htm |
| 2019-12-04 | MORGAN R BROWN | EVP and Chief Financial Office | Buy | 57,500.00 | 81,062.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919001011/0001638599-19-001011-index.htm | ||
| 2019-12-04 | Mahesh V. Patel | CEO and President | Sell | 43,500.00 | 0.41 | 17,835.00 | 908,612.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919001010/0001638599-19-001010-index.htm |
| 2019-12-10 | Mahesh V. Patel | President and CEO | Buy | 25,000.00 | 0.40 | 9,975.00 | 933,612.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919001020/0001638599-19-001020-index.htm |
| 2019-12-04 | Mahesh V. Patel | CEO and President | Buy | 145,000.00 | 952,112.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859919001010/0001638599-19-001010-index.htm | ||
| 2019-12-31 | Mahesh V. Patel | CEO and President | Buy | 40,000.00 | 0.38 | 15,340.00 | 973,612.00 | https://www.sec.gov/Archives/edgar/data/1535955/000163859920000002/0001638599-20-000002-index.htm |